Liver metastases (liver spread) from gastrointestinal neuroendocrine tumours (cancer of intestinal hormone cells which originate from the embryonic nerve cells or the embryonic outer coat) are generally treated with surgery if a complete removal is deemed possible. This is associated with a long-term survival. However, more than four-fifths of patients with liver metastases from neuroendocrine tumours cannot undergo resection of all metastatic disease. The treatment of such patients is controversial. Palliative removal of the liver spread (ie, leaving behind a part of the cancerous liver spread) or destroying a significant portion of the cancerous liver spread using radiofrequency waves (collectively called cytoreductive surgeries) are some of the options offering symptomatic relief and possible prolongation of survival. This Cochrane review attempted to answer the question of whether palliative cytoreductive surgery is better than other palliative treatments, but no randomised clinical trials were found, addressing this issue. High-quality randomised clinical trials may become feasible to perform if their conduct and study design is thoroughly considered in all their practical and methodological aspects. Pilot randomised clinical trials, which can guide the study design of definitive randomised clinical trials, are necessary.